<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775329</url>
  </required_header>
  <id_info>
    <org_study_id>SIBOC</org_study_id>
    <nct_id>NCT04775329</nct_id>
  </id_info>
  <brief_title>Primary Prophylaxis for Spontaneous Bacterial Peritonitis</brief_title>
  <acronym>SIBOC</acronym>
  <official_title>Primary Prophylaxis for Spontaneous Bacterial Peritonitis in Decompensated Chronic Liver Disease With Small Bowel Bacterial Overgrowth: A Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient with liver cirrhosis commonly have co-existing small bowel bacterial overgrowth&#xD;
      (SIBO) yet may be asymptomatic. It is unclear as to the value of treating SIBO in&#xD;
      asymptomatic individuals. Cirrhosis increase permeability of the gastrointestinal mucosa. It&#xD;
      is postulated that in cirrhosis, endotoxins translocate across the gut mucosal barrier&#xD;
      resulting in a second hit within hepatocyte perpetuating decompensation and spontaneous&#xD;
      bacterial peritonitis. We hypothesise that cirrhosis patients with concomitant SIBO are&#xD;
      particularly vulnerable for endotoxin translocation and would benefit from treatment.&#xD;
      Treatment of SIBO would reduce the risk of spontaneous bacterial peritonitis and other&#xD;
      liver-related morbidities. We aim to treat a cohort of patients with severe liver disease and&#xD;
      concomitant SIBO with antibiotics as prophylaxis and compare the risk of spontaneous&#xD;
      bacterial peritonitis, further liver-related morbidity and survival against untreated&#xD;
      asymptomatic controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Randomised, placebo-controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Spontaneous bacterial peritonitis</measure>
    <time_frame>12 months</time_frame>
    <description>To determine the rate of cirrhosis-related complications, with and without Rifaximin among decompensated cirrhosis with SIBO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of all liver related events (hepatic encephalopathy, variceal bleeding, acute on chronic liver failure)</measure>
    <time_frame>12 months</time_frame>
    <description>To study and understand the immunophysiological and gut microbiota changes associated with bowel decontamination among cirrhosis patients with SIBO using serum biomarkers.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Decompensated Cirrhosis</condition>
  <condition>Small Bowel Bacterial Overgrowth Syndrome</condition>
  <arm_group>
    <arm_group_label>Control arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin 1000mg OM</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Decompensated liver cirrhosis (Childs B &amp; C) with ascites.&#xD;
&#xD;
          -  Established diagnosis of SIBO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to treatment drugs&#xD;
&#xD;
          -  Inability to undergo test confirm the success of SIBO eradication;&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Terminal malignancy.&#xD;
&#xD;
          -  Untreated Viral Hepatitis&#xD;
&#xD;
          -  Alcoholic Liver disease with ongoing drinking.&#xD;
&#xD;
          -  Respiratory Failure&#xD;
&#xD;
          -  Recent antibiotics and proton-pump inhibitor within 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YU JUN WONG, MD, MRCP FAMS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changi General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YU JUN WONG, MD MRCP FAMS</last_name>
    <phone>69365729</phone>
    <email>eugene.wong.y.j@singhealth.com.sg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PREM HARICHANDER THURAIRAJAH, MBBS MRCP PhD</last_name>
    <email>thurairajah.prem.harichander@singhealth.com.sg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wong Yu Jun</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Jun Wong, MD, MRCP</last_name>
      <email>eugene.wong.y.j@singhealth.com.sg</email>
    </contact>
    <contact_backup>
      <last_name>Ju Yuan Toh</last_name>
      <email>ju_yuan_toh@cgh.com.sg</email>
    </contact_backup>
    <investigator>
      <last_name>Ngai Moh Law, MBBS MRCP FRCP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seok Hwee Koo, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Prem Harichander Thurairajah, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jason Chang, MBBS, MRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rifaximin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Blind Loop Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

